- I
Israel Biotech Fund
- Ron Bentsur
Ron Bentsur is a Venture Advisor at Israel Biotech Fund. Previously, Ron was the CEO of UroGen Pharma (NASDAQ: URGN), former CEO of Keryx Biopharmaceuticals (NASDAQ: KERX) leading the company to the FDA approval of AuryxiaTM, former Chief Executive Officer of XTL Biopharmaceuticals.
Org chart
This person is not in the org chart
Teams
This person is not in any teams
Offices
This person is not in any offices
Israel Biotech Fund
Israel Biotech Fund seeks high-value returns by identifying and maximizing the success of therapeutic assets of Israel-based biotech companies. Their key asset is a unique team of 25 Venture Advisors, comprised of renowned industry leaders and professionals who, together with the fund’s managing partners, provide their portfolio companies with hands-on guidance and support.
